Regis Corporation: Cutting The Dead Ends Out Of A Profitable Franchise Network

Regis Corporation is a deeply mispriced turnaround, with an intrinsic value estimate of $86.85. Read why I rate RGS stock a ...
Witfire

Unicycive OLC CRL: The CMC Failure Behind a Biotech Selloff

Unicycive OLC received a second FDA CRL over third-party manufacturing deficiencies. The case shows why CMC risk now drives ...

Two Years After 'Muldrow,' What Must a Plaintiff Show to Establish Harm From Discrimination in the Third Circuit?

Two years later, we assess the proofs needed to satisfy the Muldrow standard in the U.S. Court of Appeals for the Third ...
The Lancet

[177 Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial

Lu]Lu-edotreotide led to statistically significant and clinically meaningful improvements in progression-free survival.
Center for American ProgressOpinion

Congressional Republicans’ Big Beautiful Bill Threatens Access to Free School Meals

Students across the country could lose access to free school meals, forcing the typical family with two children to spend ...